Enjoy complimentary customisation on priority with our Enterprise License!
The global Ewing's sarcoma treatment market size is estimated to grow by USD 205.09 million at a CAGR of 6.26% between 2023 and 2028.
Ewing's Sarcoma Treatment Market Share
For More Highlights About this Report, Download Free Sample in a Minute
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
One of the key factors driving the market growth is the regulatory incentives for Ewings sarcoma treatment. This disease is a rare bone tumor that occurs in childhood. For instance, as per the NH, approximately 3 per 1 million children each year are diagnosed with an. Ewing's sarcoma. In addition, Ewing's sarcoma accounts for about 1.5 percent of all childhood cancers, and it is the second-most common type of bone tumor in children.
Moreover, As Ewing's sarcoma is a rare disease, to date, no cure has been developed for it, as rare diseases lack sponsors owing to the expensive research and the prospect of limited profit. Therefore, to overcome this challenge, regulatory authorities in several countries are granting special drug designations, such as orphan drug designation, which qualifies a drug for special financial incentives, including tax credits for qualified clinical trials. Hence, such factors drive the market growth during the forecast period.
A key factor shaping the Ewings sarcoma treatment market growth is the emergence of regenerative therapies. There have been significant advancements in terms of the treatment of metastatic Ewing's sarcoma and recurrent Ewing's tumors in the global Ewings sarcoma treatment market. In addition, one of the most advanced and extensively researched treatment methods is regenerative medicine, including gene therapy.
Moreover, in gene therapy, the mutated gene is withdrawn from the patient and is genetically modified in a laboratory and administered to the patient. The genetically modified gene replaces the mutated genes. In addition, there are several pharmaceutical companies developing and studying gene therapy to treat metastatic Ewing's sarcoma and recurrent Ewing's tumors in patients. Hence, such factors are positively impacting the market. Therefore, it is expected to drive the market growth during the forecast period.
The lack of approved therapies for Ewings sarcoma is a challenge that affects market growth. Ewing's sarcoma is a life-threatening sarcoma arising in the bone and soft tissue of adolescents and young adults. The primary tumor is treated with surgery or radiation, depending on the possibility of resection. Owing to the high rate of spreading, even in patients with localized disease, patients are also treated with chemotherapeutics, such as vincristine, doxorubicin, and cyclophosphamide, to eradicate microscopic tumors that could lead to distant metastases and death.
Furthermore, numerous clinical trials evaluating new chemotherapeutic agents against recurrent Ewing's sarcoma are underway. However, the therapies are in early-stage clinical trials and are not expected to be launched in the next five years, which may impede the growth of the global Ewings sarcoma treatment market during the forecast period.
The end-user segment includes hospitals, specialty clinics, and others. The type segment includes combination therapy and monotherapy. The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW).
The market share growth by the hospitals segment will be significant during the forecast period. This segment is the key end-users that influence market growth. In addition, manufacturers of Ewing's sarcoma treatment therapeutics focus on delivering high-quality products to hospitals to improve brand image and thereby expand their product reach. Furthermore, large hospitals, such as multispecialty hospitals, work under government sponsorship or through private entities.
Get a glance at the market contribution of various segments Download the PDF Sample
The hospitals segment was valued at USD 259.28 million in 2018. Moreover, these hospitals have more than 500 hospital beds, allowing the accommodation of individuals from within the locality and neighboring areas. In addition, they procure medical products and consumables in bulk and engage closely with many suppliers, reimbursement authorities, and government organizations. Furthermore, they also have an advanced medical infrastructure to cater to the needs of the people. Therefore, the need for Ewing's sarcoma treatment therapeutics in hospitals will increase due to the growing number of hospital admissions for surgical care. Hence, such factors are fueling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 48% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America dominates the global Ewing's sarcoma treatment market due to high prevalence and treatment accessibility. In the region's developed countries, the annual incidence of Ewing's sarcoma is significant, with 3 children per 1 million population, and 200-250 cases in the US each year. Increasing awareness and funding, supported by organizations like the Sarcoma Foundation of America, contribute to research and education. Rising research funding has led to novel therapies' development, focusing on targeted treatments and combination therapies. Industry and clinical research collaborations, such as those with Aadi Bioscience Inc., are driving growth. Limited approved therapies and upcoming late-stage drug launches further accelerate market momentum in North America.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Advantech Co. Ltd.: The company offers Ewings sarcoma treatment drugs such as INBRX-109 which is a tetravalent, agonistic antibody targeting death receptor 5 (DR5), a proapoptotic receptor for the trimeric tumor necrosis factor related apoptosis inducing ligand.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Ewing's Sarcoma Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
158 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.26% |
Market growth 2024-2028 |
USD 205.09 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.74 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 48% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Actiza Pharmaceutical Pvt. Ltd., Advantech Co. Ltd., Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol Myers Squibb Co., Cellectar Biosciences Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Fresenius Kabi AG, GlaxoSmithKline Plc, Gradalis Inc., Johnson and Johnson, LGM Pharma LLC, Merck and Co. Inc., Novartis AG, Ocean pharmaceutical, Pfizer Inc., PharmaMar SA, Salvavidas, and UPMC Hillman Cancer Center |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.